Exagen Inc. (XGN)
NGM · Common · CUSIP 30068X103
Last Price•••.••
Current Yield•.••%
Yield to Call•.••%
Yield to Worst•.••%
Free registration unlocks the quote, yield calculations, price chart and full fundamentals for XGN and every other security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Common Stock
CUSIP
30068X103
Market Cap
Small Cap
IPO
9/19/2019 · $14.00/share
Business: Exagen Inc. is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis.

Company Contact

CEO
John Aballi
CFo
Kamal Adawi
Headquarters
1261 Liberty Way, Suite C, Vista, CA 92081
Phone
760-560-1501
Investor Relations
Kamal Adawi · 760-477-5514 · KAdawi@Exagen.com
Email Form
Contact Form »
SEC EDGAR Filings
View filings »